7R5D

PARP15 catalytic domain in complex with OUL234

7R5D の概要

• エントリーDOI: 10.2210/pdb7r5d/pdb
• 関連するPDBエントリー: 7R3O 7R4A
• 分子名称: Protein mono-ADP-ribosyltransferase PARP15, 6-propan-2-yl-[1,2,4]triazolo[3,4-b][1,3]benzothiazole, DIMETHYL SULFOXIDE, ... (4 entities in total)
• 機能のキーワード: parp, inhibitor, complex, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 51174.34

構造登録者

Maksimainen, M.M.,Lehtio, L. (登録日: 2022-02-10, 公開日: 2023-01-25, 最終更新日: 2024-02-07)

主引用文献

Murthy, S.,Nizi, M.G.,Maksimainen, M.M.,Massari, S.,Alaviuhkola, J.,Lippok, B.E.,Vagaggini, C.,Sowa, S.T.,Galera-Prat, A.,Ashok, Y.,Venkannagari, H.,Prunskaite-Hyyrylainen, R.,Dreassi, E.,Luscher, B.,Korn, P.,Tabarrini, O.,Lehtio, L.
[1,2,4]Triazolo[3,4- b ]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes.
J.Med.Chem., 66:1301-1320, 2023

PubMed Abstract: We report [1,2,4]triazolo[3,4-]benzothiazole (TBT) as a new inhibitor scaffold, which competes with nicotinamide in the binding pocket of human poly- and mono-ADP-ribosylating enzymes. The binding mode was studied through analogues and cocrystal structures with TNKS2, PARP2, PARP14, and PARP15. Based on the substitution pattern, we were able to identify 3-amino derivatives (OUL243) and (OUL232) as inhibitors of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15 at nM potencies, with being the most potent PARP10 inhibitor described to date (IC of 7.8 nM) and the first PARP12 inhibitor ever reported. On the contrary, hydroxy derivative (OUL245) inhibits poly-ARTs with a selectivity toward PARP2. The scaffold does not possess inherent cell toxicity, and the inhibitors can enter cells and engage with the target protein. This, together with favorable ADME properties, demonstrates the potential of TBT scaffold for future drug development efforts toward selective inhibitors against specific enzymes.

PubMed: 36598465
DOI: 10.1021/acs.jmedchem.2c01460

実験手法

X-RAY DIFFRACTION (2.15 Å)